The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Research Report 2024
Synopsis
Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.
The global Recurrent Glioblastoma Multiforme (GBM) Treatment market was valued at US$ 463.4 million in 2023 and is anticipated to reach US$ 699.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recurrent Glioblastoma Multiforme (GBM) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recurrent Glioblastoma Multiforme (GBM) Treatment.
Report Scope
The Recurrent Glioblastoma Multiforme (GBM) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recurrent Glioblastoma Multiforme (GBM) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recurrent Glioblastoma Multiforme (GBM) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astrazeneca
Roche
GlaxoSmithKline
Merck
Pfizer
AngioChem
Vascular Biogeneics
Segment by Type
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recurrent Glioblastoma Multiforme (GBM) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.
The global Recurrent Glioblastoma Multiforme (GBM) Treatment market was valued at US$ 463.4 million in 2023 and is anticipated to reach US$ 699.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recurrent Glioblastoma Multiforme (GBM) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recurrent Glioblastoma Multiforme (GBM) Treatment.
Report Scope
The Recurrent Glioblastoma Multiforme (GBM) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recurrent Glioblastoma Multiforme (GBM) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recurrent Glioblastoma Multiforme (GBM) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astrazeneca
Roche
GlaxoSmithKline
Merck
Pfizer
AngioChem
Vascular Biogeneics
Segment by Type
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation Therapy
Chemotherapy
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recurrent Glioblastoma Multiforme (GBM) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Medications
1.2.3 Temozolomide
1.2.4 Radiosensitizers
1.2.5 Nitrosoureas Drugs
1.2.6 Radiation Therapy
1.2.7 Chemotherapy
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2019-2030)
2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Region
2.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Dynamics
2.3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Trends
2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2019-2024)
3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2023
3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2025-2030)
5 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2019-2030)
6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2019-2024)
6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2019-2030)
7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2019-2024)
7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2019-2030)
9.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2019-2024)
9.4 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astrazeneca
11.1.1 Astrazeneca Company Detail
11.1.2 Astrazeneca Business Overview
11.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.1.5 Astrazeneca Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.2.5 Roche Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 AngioChem
11.6.1 AngioChem Company Detail
11.6.2 AngioChem Business Overview
11.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.6.5 AngioChem Recent Development
11.7 Vascular Biogeneics
11.7.1 Vascular Biogeneics Company Detail
11.7.2 Vascular Biogeneics Business Overview
11.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2019-2024)
11.7.5 Vascular Biogeneics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
